After conducting a clinical trial study at Boston Children’s Hospital, scientists from Brown University recommended that a lonafarnib therapy could increase the survival rate of progeria patients. But the mode of action of lonafarnib is still uncertain.
The study did find that folic acid alone or in combination, may reduce cardiovascular diseases and strokes but niacin and antioxidants showed little effect.
Cardiovascular diseases are more prevalent in high-income countries such as India, China and US. According to WHO reports and are the leading cause of death, where around 17.7 million people die every year.
The IVD sector in the country is chiefly characterized by 70 percent laboratories offering pathology services and 30 percent entities doling out radiology and imaging services. Though domestic players are flexing their muscles and are gearing to provide new-age diagnostic services with path-breaking innovations and strategic investments, multinational companies continue to hold sway over 60% of the domestic IVD market which is expected to grow by leaps and bounds in coming times.
Studies have shown that omega-3 fatty acids regulate the functioning of proteins and keeps inflammation totally under control. Still more research work is going on, in order to connect fish and cardiovascular systems in a beneficial manner.
The University Of Kansas Medical Center is partnering with Garmin Health to foster innovation and better understand on how healthcare wearables can help in the detection and management of significant medical conditions. Their first research will focus on cardiac care and sleep apnea.
IDx, a privately held AI diagnostics company, announced today that it has filed its De Novo submission to the FDA for IDx-DR, an AI-based system for the autonomous detection of diabetic retinopathy — a leading cause of blindness. The FDA has granted IDx-DR with a “Breakthrough Device” designation, which means the submission will receive expedited review.
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit-risk profiles.
A recent study of so-called 'white coat hypertension' finds that blood pressure readings taken at the doctor's office can be less accurate and more dangerous than readings taken at home with mHealth devices.
A new report in JAMA Internal Medicine by University of Sydney and Bond University scholars weighs the risks and benefits of a recent change to blood pressure guidelines in the US.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.